{"filing":{"accession_number":"0001104659-26-111952","cik":"0001379006","ticker":"NNVC","company_name":"NANOVIRICIDES, INC.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-28","primary_document":"tm2626486d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465926111952/tm2626486d1_8k.htm"},"events":[{"id":35786,"run_id":32978,"accession_number":"0001104659-26-111952","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses extension employment agreements for two named executives—Dr. Anil Diwan (President) and Meeta Vyas (CFO)—that modify their compensatory arrangements. Dr. Diwan's extension includes a base salary of $400,000, a $2 million term life insurance policy, and a grant of 10,204 shares of Series A Preferred Stock with quarterly vesting through June 30, 2027. Ms. Vyas's extension continues her monthly compensation of $10,800 and adds a new health insurance reimbursement benefit up to $2,500 per month. These are material modifications to executive compensation arrangements disclosed under Item 5.02(e).","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39964,"accession_number":"0001104659-26-111952","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses extension employment agreements for two named executives—Dr. Anil Diwan (President) and Meeta Vyas (CFO)—that modify their compensatory arrangements. Dr. Diwan's extension includes a base salary of $400,000, a $2 million term life insurance policy, and a grant of 10,204 shares of Series A Preferred Stock with quarterly vesting through June 30, 2027. Ms. Vyas's extension continues her monthly compensation of $10,800 and adds a new health insurance reimbursement benefit up to $2,500 per month. These are material modifications to executive compensation arrangements disclosed under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:31:43.128135+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39964,"accession_number":"0001104659-26-111952","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses extension employment agreements for two named executives—Dr. Anil Diwan (President) and Meeta Vyas (CFO)—that modify their compensatory arrangements. Dr. Diwan's extension includes a base salary of $400,000, a $2 million term life insurance policy, and a grant of 10,204 shares of Series A Preferred Stock with quarterly vesting through June 30, 2027. Ms. Vyas's extension continues her monthly compensation of $10,800 and adds a new health insurance reimbursement benefit up to $2,500 per month. These are material modifications to executive compensation arrangements disclosed under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:31:43.128135+00:00","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-09-29"}]}